Hydroxychloroquine shortened hospital stay and reduced intensive care unit admissions in hospitalized COVID-19 patients
Omma et al.,
Hydroxychloroquine shortened hospital stay and reduced intensive care unit admissions in hospitalized COVID-19..,
The Journal of Infection in Developing Countries, doi:10.3855/jidc.14933
Retrospective 393 hospitalized COVID-19 patients in Turkey, showing lower ICU admission and shorter hospitalization time with HCQ. There was no significant difference for mortality. Severity was higher in the HCQ group with greater baseline ventilation, high flow oxygen, fever, and dyspnea.
risk of death, 28.2% lower, RR 0.72, p = 0.30, treatment 17 of 213 (8.0%), control 20 of 180 (11.1%), NNT 32.
|
risk of ICU admission, 50.2% lower, RR 0.50, p = 0.004, treatment 23 of 213 (10.8%), control 39 of 180 (21.7%), NNT 9.2.
|
hospitalization time, 16.7% lower, relative time 0.83, p = 0.007, treatment 213, control 180.
|
Effect extraction follows pre-specified rules prioritizing more serious outcomes. Submit updates
|
Omma et al., 31 Jan 2022, retrospective, Turkey, peer-reviewed, 11 authors, study period 1 April, 2020 - 31 December, 2020.
Abstract: Coronavirus Pandemic
Hydroxychloroquine shortened hospital stay and reduced intensive care
unit admissions in hospitalized COVID-19 patients
Ahmet Omma1, Abdulsamet Erden1,3, Hakan Apaydin1, Meryem Aslan2, Hüseyin Çamlı2, Enes Seyda
Şahiner2, Serdar Can Güven1, Berkan Armağan1, Selma Karaahmetoğlu2, Ihsan Ates2, Orhan
Kucuksahin1,3
1 Department of Internal Medicine, Division of Rheumatology, Ankara City Hospital, Ankara, Turkey
2 Department of Internal Medicine, Ankara City Hospital, Ankara, Turkey
3 Yıldırım Beyazıt University, Ankara, Turkey
Abstract
Introduction: Effectiveness of hydroxychloroquine against SARS-CoV-2 has been highly controversial. In our research, we aimed to investigate
the effects of hydroxychloroquine on disease outcomes in hospitalized patients with COVID-19.
Methodology: A total of 393 hospitalized patients with COVID-19 were retrospectively assigned to the standard of care therapy group (n =
180) or the standard of care plus hydroxychloroquine group (n = 213). The standard of care therapy comprised favipiravir, low molecular
weight heparin, acetylsalicylic acid. Status of oxygenation at baseline and on the seventh day, laboratory tests at baseline and at discharge were
recorded. Length of hospital stay, administration of anti-inflammatory treatment, admission to the intensive care unit and 28th day mortality
were set as primary endpoints.
Results: There were no statistically significant differences between groups in terms of oxygen delivery route and mortality after seven days of
treatment (p = 0.592). C-reactive protein levels of the standard of care plus hydroxychloroquine group were significantly lower than that of the
standard of care group at discharge (p = 0.034). Patients in the standard of care plus hydroxychloroquine group had shorter hospital stay (p =
0.007). The standard of care plus hydroxychloroquine group was favored over standard of care group in terms of rate of intensive care unit
admissions (21.7% vs. 10.8%; relative risk with 95% CI = 0.49 [0.31-0.80], p = 0.003).
Conclusions: Hydroxychloroquine in addition to standard of care was associated with less intensive care unit admissions, early discharge and
greater C-reactive protein reduction. There was no difference in 28-day mortality.
Key words: COVID-19; hydroxychloroquine; intensive care unit; mortality; inpatient duration.
J Infect Dev Ctries 2022; 16(1):25-31. doi:10.3855/jidc.14933
(Received 19 February 2021 – Accepted 09 May 2021)
Copyright © 2022 Omma et al. This is an open-access article distributed under the Creative Commons Attribution License, which permits unrestricted use,
distribution, and reproduction in any medium, provided the original work is properly cited.
Late treatment
is less effective
Please send us corrections, updates, or comments. Vaccines and
treatments are complementary. All practical, effective, and safe means should
be used based on risk/benefit analysis. No treatment, vaccine, or intervention
is 100% available and effective for all current and future variants. We do not
provide medical advice. Before taking any medication, consult a qualified
physician who can provide personalized advice and details of risks and
benefits based on your medical history and situation.
FLCCC and
WCH
provide treatment protocols.
Submit